Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2024-06-25 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
IMFINZI IMPROVED EFS AND OS IN BLADDER CANCER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It provides detailed clinical trial results and information about the drug Imfinzi in bladder cancer, including trial design, endpoints, and regulatory context. The document is not an annual or quarterly financial report, nor is it an earnings release or management discussion. It is a regulatory filing used by foreign companies to report material information to the SEC. The length and content indicate it is a substantive report but not a financial report like 10-K or IR. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2024-06-25 English
Update on Imfinzi ADJUVANT BR.31 trial
Regulatory Filings Classification · 99% confidence The document begins with an RNS Number (7457T) and is dated June 25, 2024. It announces an 'Update on ADJUVANT BR.31 Phase III trial of Imfinzi' and details the results (did not achieve statistical significance for the primary endpoint). The text concludes with contact information for Investor Relations and a footer explicitly stating, 'This information is provided by RNS, the news service of the London Stock Exchange.' This structure—a brief announcement of material, non-financial or clinical development news disseminated via the RNS system—is characteristic of a general regulatory announcement rather than a comprehensive financial report (like 10-K or IR) or a specific management/governance filing. Since it is a general regulatory announcement that doesn't fit the other specific categories (like DIRS, DIV, ER, etc.), the most appropriate fallback category is Regulatory Filings (RNS). The document length (14,467 chars) is substantial enough that it is not merely an announcement *of* a report, but the report/update itself.
2024-06-25 English
Imfinzi improved EFS and OS in bladder cancer
Legal Proceedings Report Classification · 99% confidence The document begins with 'RNS Number : 7449T' and is dated '25 June 2024'. It details positive clinical trial results for a drug (Imfinzi) and concludes with standard boilerplate text referencing RNS, the London Stock Exchange, and the Financial Conduct Authority (FCA). This structure is characteristic of a regulatory news service announcement, which serves as a general disclosure mechanism for material information that doesn't fit a more specific SEC filing category (like 10-K or DEF 14A). Since it is a broad regulatory announcement provided via RNS, the most appropriate classification is Regulatory Filings (RNS). It is not a full Annual Report (10-K), an Earnings Release (ER), or a specific management/board change (MANG).
2024-06-25 English
UPDATE ON CAPITELLO-290 PHASE III TRIAL
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It provides an update on the CAPItello-290 Phase III clinical trial results, including detailed clinical and scientific information about the trial outcomes, safety profile, and ongoing research programs. The document is not an annual or quarterly financial report, nor is it a transcript, audit, or governance document. It is a regulatory filing used by foreign companies to report material information to the SEC. The length of the document (11,755 characters) and the detailed content confirm it is a substantive report rather than a brief announcement. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2024-06-18 English
Update on CAPItello-290 Phase III trial
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number : 8458S' and includes standard boilerplate language referencing RNS, the London Stock Exchange, and the Financial Conduct Authority (FCA) at the end. This strongly indicates it is a regulatory news service announcement. The content is an update on a clinical trial ('Update on the CAPItello-290 Phase III trial') which is a material event for a pharmaceutical company. Since this is a specific announcement of clinical trial results (not a full financial report like 10-K or IR, nor a general press release), it fits best under the general 'Regulatory Filings' category (RNS) as it is disseminated via the RNS system, or potentially an 'LTR' (Legal/Regulatory/Trial Update), but RNS is the most accurate descriptor for the dissemination mechanism and format. Given the options, RNS is the most appropriate catch-all for specific, non-financial regulatory news disseminated through this channel.
2024-06-18 English
IMFINZI APPROVED IN THE US FOR ENDOMETRIAL CANCER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It provides detailed information about the FDA approval of Imfinzi for endometrial cancer, including clinical trial results, drug information, and company background. The document is not an annual or quarterly financial report, nor is it an earnings release or management discussion. It is a regulatory filing providing material information about a significant corporate event (drug approval) but does not fit into categories like M&A, capital update, or governance. The Form 6-K is a standard SEC filing for foreign issuers to report material information and is classified under Regulatory Filings (RNS). The document length (over 14,000 characters) and content confirm it is a substantive report, not just an announcement of a report publication. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-06-17 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.